Bristol Myers Squibb and AstraZeneca are reportedly in early merger talks that could create a combined entity worth roughly $400 billion, according to a Financial Times report, potentially one of the largest deals in pharmaceutical history.

AstraZeneca, the UK's second-largest listed company, recently added a New York Stock Exchange listing and appears keen to strengthen its US footprint, a market that already generates over 40% of its revenue.

Yet markets reacted with unusual scepticism. AstraZeneca shares dropped nearly 7% on the news, while BMS barely moved. As Morning Brew's Brew Markets newsletter noted, analysts at RBC, Jefferies, UBS, and Barclays all expressed confusion rather than enthusiasm - AstraZeneca is performing well on its own, driven by its rare disease and obesity pipeline following the Alexion acquisition, while BMS is grappling with looming patent cliffs for its top-selling drugs and the aftermath of an underwhelming Celgene deal. Heavy overlap in oncology revenue between the two firms also raises the likelihood of extended antitrust scrutiny.

The speculation comes as healthcare M&A activity gathers pace in 2026. Industry data indicate that pharmaceutical companies have announced more than $100 billion in transactions this year, supported by strong balance sheets, favourable financing conditions and the need to offset revenue losses from upcoming patent expirations. Large pharmaceutical groups are increasingly targeting acquisitions to expand therapeutic pipelines, strengthen innovation capabilities and secure exposure to high-growth areas including oncology, rare diseases and next-generation biologics.

Whether the proposed AstraZeneca–Bristol Myers combination ultimately materialises or not, the market's response underscores a broader reality: strategic acquisitions are once again becoming a defining feature of the global pharmaceutical industry, with scale, innovation and pipeline diversification emerging as the primary drivers of corporate value creation.

- Emmanuel Chukwuani and Saiee Katarkar

The Japanese yen has climbed to its strongest level in three months after Japan and the United States launched a coordinated intervention to support the currency. 

By Monday, the yen had strengthened to around ¥155 against the US dollar after plunging to a 40-year low of almost ¥164 last week. Bank of Japan data suggested that Tokyo sold nearly $59 billion worth of US dollars to purchase yen during its intervention in New York markets on Thursday.

The move marks the second coordinated currency intervention between Japan and the US, following the first intervention in 2011, when both countries acted together to weaken the yen following the Tohoku earthquake. 

The intervention now comes as Japan continues to face economic challenges. The Bank of Japan most recently raised its policy interest rate to 1%, its highest level since 1995, yet remains well below other advanced economies such as the US Federal Reserve's benchmark rate of 3.50%–3.75%. Japan's low interest rates make the yen popular for "carry trade": a strategy in which investors borrow cheaply in yen to invest in higher-yielding assets, particularly US dollar-denominated investments. This persistent selling of yen has placed downward pressure on the currency. Japan also continues to face structural challenges, including weak productivity growth, an ageing population, and heavy reliance on imported energy. 

Attention now turns to whether Japan can sustain the yen without continued US support. While intervention may provide short-term relief, a reliance on the US could signal deeper structural weaknesses in Japan's economy.

- Ebbawaaq Adamu

Spotify has forecast weaker-than-expected user growth despite continuing to expand its global subscriber base, highlighting the challenges facing the maturing music streaming industry. The company expects monthly active users to reach 788 million in the current quarter, below analysts' expectations of 793 million, while reporting net income of €545 million on revenue of €4.8 billion. Operating expenses also rose 19% year-on-year as Spotify increased spending on marketing and artificial intelligence, reflecting a deliberate strategy to invest in future growth despite short-term pressure on profitability.

Management maintains that these higher costs are temporary and remain firmly under its control. Spotify added seven million premium subscribers during the quarter, taking its global total to 300 million, while gross margins continued to improve from about 25% in 2023 to 33% in 2026, as the company demonstrated stronger operating efficiency. At its recent investor day, Spotify outlined plans to diversify its premium offering through AI-powered remixing tools, personalised podcasts and exclusive concert ticket access, to encourage existing subscribers to upgrade to higher-priced subscription tiers rather than relying solely on user growth. These initiatives reflect a broader shift towards increasing revenue per customer as market penetration begins to slow.

The results underline a wider challenge facing technology companies as many digital platforms transition from rapid user expansion to sustainable monetisation. Investors are increasingly focused on whether artificial intelligence can unlock new revenue streams rather than simply reduce costs. For Spotify, continued investment in AI represents a strategic bet that personalised content and premium experiences will strengthen customer loyalty, support long-term profitability and reinforce its competitive position within an increasingly mature streaming market.

- Muthu Ramanathan

Until next time,

The Long and Short

Markets, Made Sense